US 12329825
Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject
granted A61KA61K2039/505A61K31/713
Quick answer
US patent 12329825 (Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject) held by Dyne Therapeutics, Inc. expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Dyne Therapeutics, Inc.
- Grant date
- Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K31/713, A61K47/10, A61K47/549